Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Neurother. 2009 Apr;9(4):565-74. doi: 10.1586/ern.09.11.

Treatment of neuro-Behçet's disease: an update.

Author information

1
Associate Professor of Neurology, Nemazee Hospital, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. borhanihaghighi@yahoo.com

Abstract

Neurological manifestations of Behçet's disease (neuro-Behçet's disease) present in 5-30% of cases. They are classified into parenchymal and nonparenchymal categories. Poor prognostic factors include multifocal involvement, spinal presentations, more than two attacks per year, progressive course and increased cerebrospinal fluid cell count and protein content at the time of neurologic manifestations. For patients with parenchymal neuro-Behçet's disease without any poor prognostic factor, azathioprine or methotrexate and corticosteroids are recommended as the first-line treatment. For high-risk patients, intravenous cyclophosphamide and corticosteroids are recommended. If these regimens failed, TNF-alpha-blocking drugs, such as infliximab or etanercept, should be added. Alternating IFN-alpha and then chlorambucil or experimental treatments are the last resorts for most refractory patients. Treatment of venous sinus thrombosis is achieved by using anticoagulation and short-term corticosteroids with or without immunosuppressants.

PMID:
19344307
DOI:
10.1586/ern.09.11
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center